IMPORTANCE Mental health (MH) conditions are undertreated in late life. It is important to identify treatment strategies that address variability in treatment content and delivery and take individual-specific symptoms into account, particularly among low-income, community-dwelling older adults.
Supplemental content at jamapsychiatry.com M ental health (MH) conditions affect individuals across the life course but are particularly underidentified, undertreated, and detrimental in later life. Such conditions serve as the catalyst for a variety of negative outcomes in older adulthood, including cognitive decline, physic al disability and morbidity, loss of independence, institutionalization, and ultimately mortality. [1] [2] [3] One in 5 older adults experiences some form of MH condition, but less than 10% report receiving any MH treatment. [4] [5] [6] [7] [8] Among those who seek or receive treatment, most do so when in primary care. 8 To address logistic and system-level barriers and optimize outcomes among individuals receiving MH treatment in primary care, several teams have developed and evaluated a collaborative MH care model. This model includes MH care managers who provide education, counseling, and decision support to patients and their primary care providers; a licensed MH professional (eg, psychiatrist) who supervises the care managers; and the use of an algorithm to guide and adjust pharmacological and nonpharmacological treatment plans. 9 A key feature of collaborative MH care is the use of measurementbased care, which involves frequent monitoring, as well as standardized assessments, tracking tools, and treatments that are individualized and adapted based on patient preferences, symptoms, medication adherence and tolerability, and treatment response. This greater precision in patient monitoring enables accurate and quick patient and health care professional feedback as well as modification of treatment when needed.
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The evidence base for measurement-based, collaborative MH care models is strong. 11, [15] [16] [17] [18] [19] [20] [21] [22] However, although measurement-based MH care management (CM) programs offer decision support and reduce the treatment heterogeneity that often characterizes MH care, questions remain regarding the relative effectiveness of different treatment strategies for various populations. For example, several collaborative care trials have shown limited benefits of both psychotropic medication and intensive MH CM for older adults with subsyndromal or even mild depressive disorder. 16, 23, 24 In addition, almost all of the randomized clinical trials to date have focused on multifaceted programs delivering intense services. There is little evidence regarding the level of patient or health care professional support that is needed to achieve positive outcomes. Understanding the conditions in which varying intensities of MH monitoring and CM are most effective is important at many levels (eg, choosing the most appropriate treatments to attain individual-level improvement, achieving cost-efficient care, and formulating medical reimbursement policies). Moreover, although collaborative care models have been successfully implemented in a variety of settings, 16, 18, 25, 26 there is much value to be gained from examining care among specific subgroups of older adults who may be particularly vulnerable to negative outcomes. For example, older, communitydwelling adults with low income not only are more susceptible to MH conditions, such as depression, but also respond less favorably to psychotherapy and pharmacotherapy than their more affluent counterparts. 27 Factors such as medical and psychiatric comorbidity and a lack of access to and knowledge of All study procedures were approved by the University of Pennsylvania's Institutional Review Board. Individuals provided oral informed consent at the time of the baseline assessment, and every other individual was randomized to the CM arm. Oral informed consent was obtained for the assessments at 3 and 6 months after randomization, which mirrored the baseline interview in content. Research personnel were not masked to intervention arm randomization.
MA Arm
Individuals randomized to the MA arm completed a baseline assessment and up to 4 brief follow-up assessments during which time medication adherence, adverse effects, and symptoms were monitored. Interviews were conducted by health technicians or behavioral health providers (BHPs) and were completed by direct entry of clinical data into a software program (BHL, version 5. 37 and the GAD-7 for generalized anxiety symptom severity. 38 On completion of the baseline assessment, a summary of the individual's outcomes was generated for his or her prescribing professional. Individuals also were mailed educational materials regarding specific reported symptoms. Individuals in the MA arm also received up to 4 brief (5-10 minutes) structured assessments after the baseline assessment. These brief follow-up contacts took place during the initial 12 weeks of pharmacological treatment and were designed to monitor adherence, adverse effects, and response to treatment. Structured assessments included the PHQ-9, the GAD-7, and questions regarding irritability and sleep. A progress report was provided to the prescribing professional after each interview to help in treatment planning and alert him or her to special issues (especially safety concerns).
CM Arm
Individuals randomized to the CM arm received all monitoring services described above plus CM delivered by BHPs who had expertise in MH assessment and were well versed in delivery of algorithm-based management strategies for disorders such as depression and anxiety. To help supplement and support the prescribed treatment, the roles of BHPs included facilitating treatment, engaging individuals in the treatment process, encouraging acceptance and adherence to treatment recommendations, and monitoring safety, tolerability, and response to treatment, and providing educational and problem-focused therapy using motivational interviewing techniques 39 in a manner consistent with guidelines by the priate, BHPs also connected individuals with local community services and resources. The frequency and number of contacts for each participant varied, but individuals received on average 5 telephone calls over the span of approximately 12 weeks. Individuals in the CM arm also received maintenance telephone calls at 4-month, 5-month, and 6-month followup. Written updates and algorithm-based recommendations were provided to the prescribing professional at each assessment or as clinically indicated.
Outcome Assessments
Overall MH functioning (ie, the 12-Item Short-Form Health Survey MCS score) was the primary outcome. Secondary outcomes included the PHQ-9 and GAD-7 symptom severity scores.
Statistical Analysis
Initial descriptive, univariable analyses included means and standard deviations for continuous variables and frequencies and percentages for binary variables. Baseline comparisons between treatment arms were made using the t test for continuous variables and the χ 2 test for categorical variables.
There was sufficient power (89%) for a 2-sided test (α = .05) to detect a small effect size of 0.20 for the primary outcome. To test our primary hypotheses, differences between the MA and CM arms were estimated using intent-to-treat, mixed-effects linear regression models of longitudinal data extracted from the baseline and 3-month and 6-month follow-up interviews. Individual outcomes included the 12-Item Short-Form Health Survey MCS score (range, 0-100), PHQ-9 score (range, 0-27), and GAD-7 score (range, 0-21). All 3 outcomes were treated as continuous variables. As outlined in the eText in Supplement 2, an additional series of secondary analyses examined changes in the MCS score, symptom severity, and remission rates among subgroups of individuals, including those who had higher clinically significant levels of baseline symptoms and those who were prescribed each of the 2 different medication classes. All models included fixed effects for time (a continuous variable), treatment arm, and the interaction between the 2 variables (ie, time × treatment arm). A first-order, autoregressive, residual covariance matrix structure was specified for each model. Finally, standardized mean treatment arm differences in the primary and secondary outcomes were calculated at 6-month follow-up to derive effect size estimates.
Results

Sample Characteristics, Bivariable Analyses, and Attrition
Most individuals were prescribed citalopram hydrobromide, sertraline hydrochloride, duloxetine hydrochloride, lorazepam, or alprazolam. There were no treatment arm differences in rates of medication type or dosage. Table 1 lists additional sample characteristics stratified by intervention arm. Individuals randomized to the CM arm were more likely to be female, were less likely to use alcohol, and reported poorer overall MH. An analysis of bivariable correlations among clinical and background characteristics and the 3 main outcome variables revealed that age, poor finances, high-risk suicidal ideation, and a history of depression were each related to at least 1 of the outcome variables (P ≤ .05 for all). Therefore, these variables were included in the subsequent adjusted regression models.
Comparisons of 240 individuals (23.6%) who completed only the baseline interview vs 778 individuals (76.4%) who completed at least 1 follow-up interview showed that those who were lost to attrition were more likely to be male (χ 2 2 = 6.25, P = .04) and older (F 2,1015 = 4.16, P = .02) and had higher Blessed Orientation-Memory-Concentration Test scores at baseline (F 2,1015 = 11.05, P < .001). There were no other treatment arm differences, including treatment arm randomization, nursing home placement rates, and death, across those who were lost to attrition and those who completed follow-up interviews.
Outcome Analyses
Overall MH Functioning 33 to −0.14; P < .001) were observed for the entire sample when examining change in the GAD-7 scores over time (Table 2 and Figure 3) . Specifically, relative to the MA arm, the CM arm showed greater reductions in anxiety symptoms over the course of follow-up. The effect size was 0.28 (95% CI, 0.13-0.43) at 6-month follow-up.
Discussion
The findings herein support the hypothesis that a telephonedelivered, measurement-based, collaborative MH CM program results in better overall MH functioning and greater symptom improvement compared with symptom MA. Compared with those receiving MA, individuals with moderate to severe baseline symptoms receiving CM also were more likely to achieve remission at follow-up (eText in Supplement 2). The SUSTAIN program is novel in its ability to provide services for a unique sample of vulnerable, geographically dispersed, community-dwelling older adults. The ability to identify, assess, and enroll this subsample of older adults with low refusal rates over time confirms program feasibility and scalability. Both the initial response rate of individuals who received telephone calls for a baseline clinical interview and the retention rate over time are comparable to rates from past work with communitybased samples of older adults. 4, 16, [41] [42] [43] [44] [45] The few individuals with b Data missing for 5 participants (n = 1013). Individuals were asked: "Thinking about your financial situation, would you say that you: (a) can't make ends meet, (b) have just enough to get along, or (c) are comfortable?" Individuals who endorsed "can't make ends meet" were considered to have poor finances. Approximately 70% (711 of 1013) reported they "have just enough to get along." c Individuals were excluded from the clinical service if they demonstrated severe cognitive impairment (defined as a BOMC Test score of Ն14), which limits the ability to obtain reliable self-report data.
d The 5-item Paykel Scale was used to assess for suicidal ideation. Individuals were considered to have high-risk suicidal ideation (0 if absent and 1 if present) if they endorsed "true" on any of the items 3 through 5. e Individuals were asked if they had drunk beer, wine, or liquor in the past 3 months (yes or no). f Individuals were considered to have a history of depression if they endorsed "yes" to the following 2 items: "In the past, have you ever had 2 weeks or more when nearly every day you felt blue or depressed and/or lost interest in things like work or hobbies or things you usually liked to do for fun?" and "During this time, did your work, activities, or relationship suffer?" g Medication was considered new if an individual reported taking the medication for the first time within the 6 months before the baseline clinical interview. h Overall functioning assessed with the SF-12 MCS score or PCS score. severe symptoms requiring specialty MH care and the many individuals with very mild symptoms demonstrate the need for services that differ in focus from specialty care. The inclusion of nonpsychiatric practices beyond primary care is also a novel component and has received limited attention in randomized clinical trials but represents a need when considering population health. These findings echo the results from prior clinical trials showing that measurement-based, collaborative MH care programs that involve symptom monitoring, intensive CM, and treatment algorithms are effective and associated with positive short-term and long-term outcomes. 9 Validating the symptom-level benefits were improvements in overall MH functioning herein, which were seen despite the short duration of the intervention. These results also support other findings showing that simple symptom MA is not sufficient to fully address mental illness and is most valuable in the context of treatment that includes formal clinical interpretation and structured reaction to symptom monitoring. 46 The results herein also underscore the value of structured MH CM in which individuals are monitored and the information is provided to the prescribing professional as an added resource to primary care and pharmacological management. The observed effect sizes, which were based on a comparison of 2 active treatment arms, are comparable in size to those found by Gilbody and colleagues 12 in their 2006 meta-analytic review of collaborative vs usual care for the treatment of depression and in more recent collaborative care clinical trials, 47 lending further support to the notion that the added benefit of CM is both statistically and clinically relevant. Nonetheless, future work should focus on identifying and enhancing the components of CM that are most beneficial in an effort to improve overall effectiveness. Additional work is also needed to examine the cost-effectiveness and economic implications of these findings from multiple perspectives (ie, consumer, payer, and societal). This type of work would be particularly informative among subgroups of older adults who might be especially vulnerable to mental and physical health issues and increased health care use. There are limitations to consider when interpreting the program results herein. First, information regarding the indication for the index medication prescription was not available, nor did we take into account additional prescribed psychotropic and nonpsychotropic medications. Furthermore, we did not collect data on adherence to the index medication, which is a potential mediator of treatment arm differences in outcome, during the follow-up assessments. Second, the inclusion criteria for clinically significant symptoms were somewhat broad and spanned multiple symptom domains (eg, depression, anxiety, and suicidal ideation). While the assessment and management of multiple comorbid conditions is a strength of the program, future work may benefit from more in-depth analysis of the relative effectiveness of different treatment strategies among subcategories of individuals. Third, although the 2 treatment arms provided different intensities of intervention and interaction with individuals, there remains 
